Universal Entertainment targets 2H26 Okada Manila profit after IR EBITDA falls 62.5% | AGB

URANIUM ENERGY CORP (UEC) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex_974249.htm EXHIBIT 99.1 ex_974249.htm Exhibit 99.1 NYSE American: UEC Uranium Energy Corp Reports Results for the Third Quarter of Fiscal 2026 Commenced Production at Burke Hollow, America ’ s Largest Greenfield ISR Uranium Project UEC is Now Operating Two of its Thr

MarketBeat reports that Grand View Research expects small modular and advanced reactors, plus government support, to drive long-term demand for reactor-grade uranium. It highlights Uranium Energy (UEC), which says it has $486m cash, $818m liquid assets, zero long-term debt, and 1.456m pounds of LEU. UEC reported ~46,000 pounds produced at $30.52/lb cash cost and sold 200,000 pounds at $101/lb.

Uranium Energy (UEC) shares rose about 11% Tuesday and nearly 26% over 10 sessions, reaching around 1 p.m. ET. The company said it will report quarterly earnings June 9, but the move was attributed to Urenco’s plan to expand capacity by nearly 50% at the U.S. enrichment facility, boosting expected demand for uranium feedstock amid a U.S. ban on Russian imports by Jan. 1, 2028.

The article says data-center demand is stressing power grids and could boost nuclear firms offering 24/7 baseload power, including small modular reactors (SMRs). It highlights Fluor, which will support X-Energy’s four SMRs and has a Kentucky data-center pre-construction deal; Fluor reported Q1 2026 revenue of $3.6B (-8%) and a $25.7B backlog. It also cites Uranium Energy’s $66.8M FY2025 revenue and Cameco’s CA$845M Q1 2026 revenue (+7%) and CA$131M net income (+87%).

The article says nuclear power demand could rise as data centers strain grids, boosting companies tied to small modular reactors (SMRs) and uranium supply. It highlights Fluor, which in April said it will support X-Energy’s four SMRs and reported Q1 2026 revenue of $3.6B (down 8%) with a $25.7B backlog; Uranium Energy, with FY2025 revenue of $66.8M and FY2026 Q2 revenue of $20.2M; and Cameco, reporting 2026 Q1 revenue of CA$845M (+7%) and net earnings of CA$131M (+87%).

AbbVie (ABBV) says its neuroscience portfolio is expected to generate about $12.7 billion in revenue in 2026, up by $100 million after strong first-half performance. In Q2, neuroscience revenue rose 20.3% to $3.23 billion, led by Vraylar ($1.07B), therapeutic Botox ($1.04B), Ubrelvy and Qulipta ($742M), and Vyalev ($256M).